Rhumbline Advisers Protagonist Therapeutics, Inc Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Rhumbline Advisers holds 164,178 shares of PTGX stock, worth $6.45 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

164,178

Previous 84,975 93.21%

Holding current value

$6.45 Million

Previous $2.94 Million 150.61%

% of portfolio

0.01%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$33.72 - $47.33 $2.67 Million - $3.75 Million	79,203 Added 93.21%	164,178 $7.38 Million
Q2 2024 Aug 01, 2024	SELL	$24.66 - $34.8 $345 - $487	-14 Reduced 0.02%	84,975 $2.94 Million
Q1 2024 May 09, 2024	BUY	$21.79 - $32.15 $36,977 - $54,558	1,697 Added 2.04%	84,989 $2.46 Million
Q4 2023 Feb 08, 2024	BUY	$14.05 - $23.44 $6,786 - $11,321	483 Added 0.58%	83,292 $1.91 Million
Q3 2023 Nov 09, 2023	BUY	$16.68 - $23.66 $81,698 - $115,886	4,898 Added 6.29%	82,809 $1.38 Million
Q2 2023 Aug 08, 2023	BUY	$18.02 - $29.36 $57,700 - $94,010	3,202 Added 4.29%	77,911 $2.15 Million
Q1 2023 May 11, 2023	BUY	$10.78 - $25.38 $38,333 - $90,251	3,556 Added 5.0%	74,709 $1.72 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $4,680 - $7,104	636 Added 0.9%	71,153 $776,000
Q3 2022 Nov 10, 2022	BUY	$7.86 - $11.71 $31,054 - $46,266	3,951 Added 5.94%	70,517 $594,000
Q2 2022 Aug 11, 2022	BUY	$7.06 - $25.52 $142,188 - $513,972	20,140 Added 43.38%	66,566 $527,000
Q1 2022 May 12, 2022	BUY	$23.34 - $36.08 $57,346 - $88,648	2,457 Added 5.59%	46,426 $1.1 Million
Q4 2021 Feb 10, 2022	BUY	$17.63 - $37.1 $22,460 - $47,265	1,274 Added 2.98%	43,969 $1.5 Million
Q3 2021 Nov 12, 2021	BUY	$12.95 - $49.69 $24,384 - $93,566	1,883 Added 4.61%	42,695 $757,000
Q2 2021 Aug 05, 2021	BUY	$25.57 - $44.88 $194,255 - $340,953	7,597 Added 22.87%	40,812 $1.83 Million
Q1 2021 May 06, 2021	SELL	$19.02 - $31.15 $9,890 - $16,198	-520 Reduced 1.54%	33,215 $860,000
Q4 2020 Feb 10, 2021	BUY	$18.49 - $25.13 $79,303 - $107,782	4,289 Added 14.57%	33,735 $680,000
Q3 2020 Nov 12, 2020	SELL	$15.19 - $22.4 $3,493 - $5,152	-230 Reduced 0.78%	29,446 $576,000
Q2 2020 Aug 13, 2020	BUY	$6.19 - $18.84 $80,500 - $245,014	13,005 Added 78.01%	29,676 $524,000
Q1 2020 May 06, 2020	BUY	$5.4 - $9.22 $2,052 - $3,503	380 Added 2.33%	16,671 $118,000
Q4 2019 Feb 05, 2020	BUY	$4.69 - $13.45 $3,522 - $10,100	751 Added 4.83%	16,291 $115,000
Q3 2019 Oct 23, 2019	BUY	$9.41 - $16.56 $25,049 - $44,082	2,662 Added 20.67%	15,540 $187,000
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $115,644 - $166,898	12,878 New	12,878 $156,000
Q2 2018 Aug 06, 2018	SELL	$5.99 - $9.1 $61,661 - $93,675	-10,294 Closed	0 $0
Q1 2018 May 02, 2018	BUY	$8.46 - $23.08 $87,087 - $237,585	10,294 New	10,294 $88,000
Q4 2017 Feb 09, 2018	SELL	$14.47 - $20.8 $146,089 - $209,996	-10,096 Closed	0 $0
Q3 2017 Nov 06, 2017	BUY	$10.61 - $17.98 $107,118 - $181,526	10,096	10,096 $178,000

Others Institutions Holding PTGX

# of Institutions

248

Shares Held

56.7M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Protagonist Therapeutics, Inc Transaction History